This review focuses on the subgroup of patients with an asthma phenotype predisposed to poor control a with conventional treatment strategy; the rationale for a single-inhaler, triple-therapy combination for this population; and evidence supporting its approval for clinical use.
“We suggest that, whenever possible, all PAH patients be evaluated promptly at a center with expertise in the diagnosis of PAH, ideally before the initiation of therapy.”(Ungraded consensus-based statement7) “We suggest also that contributing causes of PH (eg, sleep apnea and systemic hypertension) in patients with PAH be treated aggressively.”(Ungraded consensus-based statement7) “We suggest collaborative…
Eosinophilic granulomatosis with polyangiitis (EGPA), formerly known as Churg-Strauss syndrome, has now drawn attention with the publication of results from several clinical trials. The main targets of eosinophilic inflammation — interleukin (IL)-5 and T-helper-2 cells — cause a constellation of symptoms including asthma, sinusitis, eosinophilia, and necrotizing vasculitis.1,2 For years, oral glucocorticoids were considered first-line…
